-
Phase 1/2 trial of exon 44 skipping therapy for DMD cleared in UK
Entrada Therapeutics announced it has been cleared in the U.K. to start a Phase 1/2 […]
-
Cumberland Pharmaceuticals announced positive cardiac results from Phase 2 trial in Duchenne
Cumberland Pharmaceuticals announced positive cardiac results from Phase 2 trial in Duchenne Cumberland Pharmaceuticals released […]
-
Entrada Therapeutics gets ok to start Exon 44 skipping trial in UK
As an early funder of Entrada, CureDuchenne is pleased to share that Entrada received authorization […]
-
To a parent, the years always seem too short
I read a quote the other day on Facebook: “When you are raising babies, you […]
-
CureDuchenne Announces Educational Events for Families and Caregivers of Individuals with Duchenne or Becker Muscular Dystrophy
Upcoming Events Offer Treatment Updates and Essential Resources to Support Families and Enhance Quality of […]
-
MDA honors researcher, patient advocate with 2025 Legacy Awards
The Muscular Dystrophy Association (MDA) has announced its 2025 Legacy Awards, and will honor two […]
-
Another fall left me feeling like an upside-down turtle
About a month ago, I came home from playing with my church’s music group at […]
-
How a Singapore ‘Artist’s Way’ program is rekindling my creativity
Rediscovering my creative self has been one of the most fulfilling yet challenging parts of […]
-
Boys with DMD given Elevidys two years ago still showing motor gains
Two years after receiving the gene therapy Elevidys (delandistrogene moxeparvovec-rokl), motor function continues to improve […]
-
Sarepta’s EMBARK study data shows continuing benefits to ambulatory individuals treated with their microdystrophin gene therapy, Elevidys
Sarepta Therapeutics shared positive topline results from Part 2 of the EMBARK study, showing that […]
